Medco Health Solutions, Inc. (NYSE: MHS) is pioneering
The world's most advanced pharmacy
® and its clinical research and innovations are part of
Medco making medicine smarter™ for millions of Americans.
With more than 20,000 employees worldwide dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2011 revenue of
$70 billion, Medco ranks 34th on the 2011
Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.
For more information, go to
About Quest Diagnostics and Berkeley HeartLab
Quest Diagnostics, the world's leading diagnostic testing company, offers genetic and non-genetic testing through Berkeley HeartLab, the company's business unit specializing in advanced cardiovascular disease testing. Berkeley HeartLab offers the 4myheart program, an educational program for patients that provides personalized care, including for medication adherence, to help patients improve their cardiac health. Quest Diagnostics offers a laboratory-developed test for the
gene variant through Berkeley HeartLab. For more information, visit
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.